An article in the Jan. 6 issue of BioWorld concerning TelorOphthalmic Pharmaceuticals should have said that the company willdevelop an eyedropper formulation of ethacrynic acid as well as anew class of molecules with similar properties.

(c) 1997 American Health Consultants. All rights reserved.